RAPT Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-03-04
- Employees
- 131
- Market Cap
- $80.9M
- Website
- http://rapt.com
- Introduction
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Study of RPT193 in Healthy Adult Male Subjects
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06087978
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05935332
- Locations
- 🇺🇸
Coral Research Clinical Corp, Miami, Florida, United States
🇵🇱NZOZ Poradnie Specjalistyczne Atopia, Kraków, Poland
🇵🇱Specjalistyczna Przychodnia Lekarska Alergo-Med sp. z o.o, Poznań, Poland
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT05399368
- Locations
- 🇺🇸
Indiana Clinical and Translational Sciences Institute (CTSI) Clinical Research Center, Indianapolis, Indiana, United States
🇺🇸Wallace Medical Group, Los Angeles, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
FLX475 in Combination With Ipilimumab in Advanced Melanoma
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04894994
- Locations
- 🇺🇸
Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04271514
- Locations
- 🇺🇸
Lenus Research & Medical Group, Miami, Florida, United States
🇺🇸Clinical Trials Management,LLC, Metairie, Louisiana, United States
🇳🇱PRA, Groningen, Netherlands
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT03674567
- Locations
- ðŸ‡ðŸ‡°
Prince of Wales Hospital, Shatin, Hong Kong
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸University of Washington, Seattle, Washington, United States
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02335814
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States